{"id":"NCT02736175","sponsor":"Ocular Therapeutix, Inc.","briefTitle":"OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","officialTitle":"A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase 3C Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2016-05","completion":"2016-07","firstPosted":"2016-04-13","resultsPosted":"2017-10-11","lastUpdate":"2017-11-13"},"enrollment":438,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Post-Surgical Ocular Pain","Post-Surgical Ocular Inflammation"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"OTHER","name":"Placebo Vehicle","otherNames":[]}],"arms":[{"label":"OTX-DP","type":"EXPERIMENTAL"},{"label":"PV","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who had undergone cataract extraction with intraocular lens implantation","primaryOutcome":{"measure":"Absence of Anterior Chamber Inflammation","timeFrame":"Day 14","effectByArm":[{"arm":"OTX-DP","deltaMin":52.3,"sd":null},{"arm":"Placebo Vehicle","deltaMin":31.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":216},"commonTop":["Adverse Events"]}}